BR0114552A - N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia - Google Patents

N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia

Info

Publication number
BR0114552A
BR0114552A BR0114552-5A BR0114552A BR0114552A BR 0114552 A BR0114552 A BR 0114552A BR 0114552 A BR0114552 A BR 0114552A BR 0114552 A BR0114552 A BR 0114552A
Authority
BR
Brazil
Prior art keywords
benzenesulfonyl
therapy
substituted
indoles
compounds
Prior art date
Application number
BR0114552-5A
Other languages
English (en)
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003810A external-priority patent/SE0003810D0/xx
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of BR0114552A publication Critical patent/BR0114552A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"N1- (BENZENOSULFONIL) INDóIS 2-, 3-, 4-, OU 5- SUBSTITUìDOS E SEU USO EM TERAPIA". A presente invenção proporciona compostos de N1-(benzenosulfonil)indóis 2-, 3-, 4-, ou 5-substituídos de fórmula geral (I), em que Ar, R^ 2^, R^ 3^, R^ 4^ e R^ 5^ são como definidos no presente relatório descritivo. Os ditos compostos possuem afinidade pelo receptor 5-HT~ 6~ e são de utilidade no tratamento e profilaxia de distúrbios correlacionados ao dito receptor, tais como, obesidade e distúrbios do sistema nervoso central (CNS).
BR0114552-5A 2000-10-20 2001-10-19 N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia BR0114552A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0003810A SE0003810D0 (sv) 2000-10-20 2000-10-20 Novel compounds their use and preparations
US24311500P 2000-10-25 2000-10-25
PCT/SE2001/002319 WO2002032863A1 (en) 2000-10-20 2001-10-19 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy

Publications (1)

Publication Number Publication Date
BR0114552A true BR0114552A (pt) 2003-07-01

Family

ID=26655269

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114552-5A BR0114552A (pt) 2000-10-20 2001-10-19 N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia

Country Status (14)

Country Link
US (2) US7087750B2 (pt)
EP (1) EP1326830A1 (pt)
KR (1) KR100823908B1 (pt)
AU (2) AU2001296193B2 (pt)
BR (1) BR0114552A (pt)
CA (1) CA2422717A1 (pt)
EA (1) EA006132B1 (pt)
HK (1) HK1084109A1 (pt)
IL (1) IL154685A0 (pt)
MX (1) MXPA03003397A (pt)
NO (1) NO325259B1 (pt)
NZ (1) NZ524675A (pt)
PL (1) PL361887A1 (pt)
WO (1) WO2002032863A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032863A1 (en) 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1343756A2 (en) * 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US20050176705A1 (en) * 2000-11-24 2005-08-11 Bromidge Steven M. Compounds useful in the treatment of cns disorders
KR20030062440A (ko) 2000-12-22 2003-07-25 와이어쓰 5-하이드록시트립트아민-6 리간드로서의헤테로사이클릴알킬인돌 또는 헤테로사이클릴아자인돌화합물
AU2002309435B2 (en) 2001-06-11 2008-08-14 Biovitrum Ab (Publ) Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes
EP1401812B1 (en) * 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2003013510A1 (en) * 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
KR100974901B1 (ko) * 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
TWI268928B (en) * 2002-03-27 2006-12-21 Glaxo Group Ltd Novel quinoline compounds, the processes for their preparation, the compositions containing them and their uses as medicaments
EP1513839B1 (en) * 2002-05-30 2006-07-26 Neurosearch A/S 3-substituted quinuclidines and their use
KR100657056B1 (ko) * 2002-06-05 2006-12-13 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료를 위한 5-ｈｔ6-수용체조절제로서 1-설폰일-4-아미노알콕시 인돌 유도체
NZ552283A (en) * 2002-06-20 2008-07-31 Biovitrum Ab Publ New compounds useful for the treatment of obesity, type II diabetes and CNS disorders
US7943639B2 (en) 2002-06-20 2011-05-17 Proximagen Limited Compounds
JP4267573B2 (ja) * 2002-09-17 2009-05-27 エフ．ホフマン−ラ ロシュ アーゲー ２，４−置換インドールおよびそれらの５−ｈｔ６モジュレーターとしての使用
AU2003283265B2 (en) * 2002-10-18 2009-03-05 F. Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-HT6 receptor affinity
ATE401307T1 (de) * 2002-11-28 2008-08-15 Suven Life Sciences Ltd N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
CA2515571A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
WO2007098418A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
US7812017B2 (en) 2006-07-03 2010-10-12 Biovitrum Ab (Publ.) 4-substituted indole and indoline compounds
BRPI0808791A2 (pt) 2007-03-13 2017-05-02 Biovitrum Ab (Publ) derivados tricíclicos de isoquinolina para tratamento de obesidade
ES2389958T3 (es) * 2007-03-21 2012-11-05 Glaxo Group Limited Uso de derivados de quinolina en el tratamiento del dolor
JP2010528037A (ja) * 2007-05-24 2010-08-19 メモリー・ファーマシューティカルズ・コーポレイション ５−ｈｔ６受容体親和性を有する４’置換化合物
US20090069337A1 (en) * 2007-08-15 2009-03-12 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-ht6 receptor affinity
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
UA100192C2 (en) * 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
WO2011088836A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
PL395469A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
JP6515175B2 (ja) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族ヘテロ環誘導体及びその医薬的適用
HUE044011T2 (hu) * 2014-08-16 2019-09-30 Suven Life Sciences Ltd 1-[(2-bromofenil) szulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1H-indol dimezilát monohidrát aktív metabolitja és az aktív metabolit dimezilát dihidrát sója
CA2989343A1 (en) 2015-06-12 2016-12-15 Yandong Wen Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263508B (pt) * 1991-02-12 1995-11-21 Pfizer
JPH04273857A (ja) * 1991-02-26 1992-09-30 Taisho Pharmaceut Co Ltd Ｎ−置換フェニルスルホニルインドール誘導体
JPH04321671A (ja) * 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
TW263504B (pt) * 1991-10-03 1995-11-21 Pfizer
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
IT1282797B1 (it) * 1995-04-21 1998-03-31 Colla Paolo Pirril-(indolil)-aril-sulfoni e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids
AU5772196A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
EP0952824B1 (en) * 1996-06-06 2004-09-29 Bifodan A/S Enteric coating, comprising alginic acid, for an oral preparation
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US6482860B1 (en) * 1996-07-19 2002-11-19 Tularik Inc. Pentafluorobenzenesulfonamides and analogs
JPH10298011A (ja) * 1997-04-30 1998-11-10 Nippon Soda Co Ltd ピリジルインドール化合物および農園芸用殺菌剤
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
EP0909762B1 (de) 1997-10-14 2003-04-09 Lonza A.G. Zweikernige Iridium(I)-phosphinkomplexe und ihre Verwendung als Katalysator in der asymmetrischen Hydroaminierung von Olefinen
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6133287A (en) * 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
WO1999065492A1 (en) * 1998-06-19 1999-12-23 Eli Lilly And Company Inhibition of serotonin reuptake
CA2353962C (en) 1998-12-11 2009-09-29 Virginia Commonwealth University Selective 5-ht6 receptor ligands
HU229479B1 (en) * 2000-02-16 2014-01-28 Glaxo Group Ltd Pyrimidine-4-one derivatives
BR0111747A (pt) * 2000-06-28 2003-07-08 Smithkline Beecham Plc Processo de moagem úmida
US6818639B2 (en) * 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
WO2002032863A1 (en) 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1343756A2 (en) 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2002042293A1 (en) * 2000-11-21 2002-05-30 Smithkline Beecham P.L.C. Isoquinoline derivatives useful in the treatment of cns disorders
US20050176705A1 (en) 2000-11-24 2005-08-11 Bromidge Steven M. Compounds useful in the treatment of cns disorders
US6951823B2 (en) * 2001-05-14 2005-10-04 Axcelis Technologies, Inc. Plasma ashing process
US6630406B2 (en) * 2001-05-14 2003-10-07 Axcelis Technologies Plasma ashing process
EP1401812B1 (en) * 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
US7279353B2 (en) * 2003-04-02 2007-10-09 Micron Technology, Inc. Passivation planarization
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds

Also Published As

Publication number Publication date
NO20031589L (no) 2003-05-28
AU9619301A (en) 2002-04-29
CA2422717A1 (en) 2002-04-25
EP1326830A1 (en) 2003-07-16
US20050256106A1 (en) 2005-11-17
US7087750B2 (en) 2006-08-08
KR20030038825A (ko) 2003-05-16
NZ524675A (en) 2004-09-24
MXPA03003397A (es) 2004-06-30
KR100823908B1 (ko) 2008-04-21
US7524839B2 (en) 2009-04-28
HK1084109A1 (en) 2006-07-21
US20020165251A1 (en) 2002-11-07
IL154685A0 (en) 2003-09-17
EA200300492A1 (ru) 2003-10-30
PL361887A1 (en) 2004-10-04
EA006132B1 (ru) 2005-10-27
NO325259B1 (no) 2008-03-17
AU2001296193B2 (en) 2006-04-27
WO2002032863A1 (en) 2002-04-25
NO20031589D0 (no) 2003-04-08

Similar Documents

Publication Publication Date Title
BR0114552A (pt) N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia
BR0214024A (pt) Derivados de 1,2,4-tiadiazol como moduladores de receptor de melanocortina
BR0314059A (pt) Compostos heterocìclicos
TR199700749T1 (xx) 5-HT resept�r antagonisti olarak indole t�revleri.
BRPI0411470A (pt) derivados de benzazepina úteis para o tratamento de doenças associadas com o receptor de 5ht2c
BR0312759A (pt) Derivados de 1-heterociclilalquil-3-sulfonilindol ou -indazol como ligantes de 5-hidroxitriptamina-6
BG108683A (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
DK0772603T3 (da) Substituerede pyrimidinforbindelser og deres anvendelse
BR0311436A (pt) Derivados de 1-(aminoalquil)-3-sulfoni-lindol e -indazol como ligandos da 5-hidroxitriptamina-6
NO305600B1 (no) Diazabicykliske neurokinin-antagonister og farmas°ytisk preparat pÕ basis av disse
BR0312758A (pt) Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6
IL151695A0 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
BRPI0418149A (pt) derivados heterocìclicos como agonistas do receptor de gprc
GB0504828D0 (en) Therapeutic agents
BR0116379A (pt) Antagonistas de receptor y5 de neuropeptìdeo y de uréia de heteroarila
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
TR200201057T2 (tr) P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları.
MXPA04001037A (es) Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PT912176E (pt) Utilizacao de amidas do acido piridil-alcanoico piridil-alcenoico e/ou piridil-alcinico para o tratamento de tumores ou para imunossupressao
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
BR0111567A (pt) Ligandos do receptor de melanocortina
NO20000521D0 (no) 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 på fenylringen
BR0209056A (pt) Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOVITRUM AB (PUBL) (SE)

Free format text: ALTERADO DE: BIOVITRUM AB

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.